Dibasic non-imidazole histamine H3 receptor antagonists with a rigid biphenyl scaffold

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 15, 2006, Pages 4063-4067

  Morini, Giovanni ^a   Comini, Mara ^a   Rivara, Mirko ^a   Rivara, Silvia ^a   Lorenzi, Simone ^a   Bordi, Fabrizio ^a   Mor, Marco ^a   Flammini, Lisa ^a   Bertoni, Simona ^a   Ballabeni, Vigilio ^a   Barocelli, Elisabetta ^a   Plazzi, Pier Vincenzo ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Biphenyl; Dibasic; H3 receptor antagonists; Histamine; Non imidazole

Indexed keywords

1,1' [BIPHENYL 4,4' DIYLBIS(METHYLENE)]BISPIPERIDINE; ALKYL GROUP; AMINE; BIPHENYL DERIVATIVE; CARBENOID; HISTAMINE H3 RECEPTOR ANTAGONIST; HISTAMINE RECEPTOR; IMIDAZOLE DERIVATIVE; PHENYL GROUP; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; NONHUMAN;

ANIMALS; CELL LINE; GUINEA PIGS; HISTAMINE ANTAGONISTS; HUMANS; IMIDAZOLES; MODELS, MOLECULAR; RATS; RECEPTORS, HISTAMINE H3;

EID: 33746894730     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.04.092     Document Type: Article

References (31)

1. Hough L.B. Mol. Pharmacol. 59 (2001) 415
2. Arrang J.M., Garbag M., and Schwartz J.-C. Nature (London) 302 (1983) 832
3. Ligneau X., Garbarg M., Vizuete M.L., Diaz J., Purand K., Stark H., Schunack W., and Schwartz J.-C. J. Pharmacol. Exp. Ther. 271 (1994) 452
4. Molderings G.J., Weibenborn G., Schlicker E., Likungu J., and Göthert M. Naunyn-Schmiedebergs Arch. Pharmacol. 346 (1992) 46
5. Clapham J., and Kilpatrick G.J. Br. J. Pharmacol. 107 (1992) 919
6. Schlicker E., Fink K., Detzner J., and Göthert M. J. Neural. Transm. 93 (1993) 1
7. Burgaud J.L., and Oudart N. J. Pharm. Pharmacol. 45 (1993) 955
8. Passani M.B., Lin J.-S., Hancock A., Crochet S., and Blandina P. Trends Pharm. Sci. 25 (2004) 618
9. Celanire S., Wijtmans M., Talaga P., Leurs R., and de Esch J.P. Drug Discov. Today 10 (2005) 1613
10. Esbenshade T.A., Fox G.B., and Cowart M.D. Mol. Interv. 6 (2006) 77
11. Leurs R., Bakker R.A., Timmerman H., and de Esch I.J.P. Nat. Rev. Drug Discov. 4 (2005) 107
12. Barocelli E., Ballabeni V., Manenti V., Flammini L., Bertoni S., Morini G., Comini M., and Impicciatore M. Pharmacol. Res. 53 (2006) 226
13. Rivara M., Zuliani V., Cocconcelli G., Morini G., Comini M., Rivara S., Mor M., Bordi F., Barocelli E., Ballabeni V., Bertoni S., and Plazzi P.V. Bioorg. Med. Chem. 14 (2006) 1413
14. Howard, H. R.; Wlodecki, B. PCT Int. Appl. WO 05105744, 2005.
15. Marquais-Bienewald, S.; Hoelzl, W.; Preuss, A.; Mehlin, A.; Brunner, F. PCT Int. Appl. WO 04035521, 2004.
16. Binet J., Thomas D., Benmbarek A., De Fornel D., and Reaut P. Chem. Pharm. Bull. 50 (2002) 316
17. Rosa J.C., Galanakis D., Piergentili A., Bhandari K., Ganellin C.R., Dunn P.M., and Jenkinson D.H. J. Med. Chem. 43 (2000) 420
18. Prof. Dr. J. Beger und Dipl.-Ing. U. Beger LaboTest OHG, Falkenberger Str. 4, D-09600 Niederschöna, Germany. Web address: www.labotest.com.
19. Lovenberg T.W., Roland B.L., Wilson S.J., Jiang X., Pyati J., Huvar A., Jackson M.R., and Erlander M.G. Mol. Pharmacol. 55 (1999) 1101
20. Plazzi P.V., Bordi F., Mor M., Silva C., Morini G., Caretta A., Barocelli E., and Vitali T. Eur. J. Med. Chem. 30 (1995) 881
21. i values according to Cheng and Prusoff's equation. Cheng Y.C., and Prusoff W.H. Biochem. Pharmacol. 22 (1973) 3099
22. Barocelli E., Ballabeni V., Caretta A., Bordi F., Silva C., Morini G., and Impicciatore M. Agents Actions 38 (1993) 158
23. Ellman G.L., Courtney K.D., Andres Jr. V., and Feather-Stone R.M. Biochem. Pharmacol. 7 (1961) 88
24. Szendey G.L. Arzneim.-Forsch 22 (1972) 1746
25. -1 substrate solution (chlorophenol red beta-d-galactopyranoside; Roche Molecular Biochemicals, Indianapolis, IN, USA) and quantitated on a microplate reader at absorbance 570 nm after overnight incubation at 20 °C.
26. Lorenzi S., Mor M., Bordi F., Rivara S., Rivara M., Morini G., Bertoni S., Ballabeni V., Barocelli E., and Plazzi P.V. Bioorg. Med. Chem. 13 (2005) 5647
27. Glide 3.5, Schrödinger. L.L.C., NY. Friesner R.A., Banks J.L., Murphy R.B., Halgren T.A., Klicic J.J., Mainz D.T., Repasky M.P., Knoll E.H., Shelley M., Perry J.K., Shaw D.E., Francis P., and Shenkin P.S. J. Med. Chem. 47 (2004) 1739
28. Automated docking was performed on 5 in its diprotonated state, starting from a minimum energy conformation placed in an arbitrary position, within a box centered on Asp114 and including the extracellular portion of the receptor. Docking solutions were ranked according to their Emodel values.
29. MD simulations were performed with Macromodel 8.5 (Schrödinger. L.L.C., NY), applying MMFF94 force field, with a time step of 1 fs, for 1 ns at 310 °K after 100 ps of equilibration, with fixed protein backbone.
30. Axe F.U., Bembenek S.D., and Szalma S. J. Mol. Graph. Model 24 (2005) 44
31. Yao B.B., Hutchins C.W., Carr T.L., Cassar S., Masters J.N., Bennani J.L., Esbenshade T.A., and Hancock A.A. Neuropharmacology 44 (2003) 773